7OA4 image
Entry Detail
PDB ID:
7OA4
Keywords:
Title:
Crystal structure of the N-terminal endonuclease domain of La Crosse virus L-protein bound to compound L-742,001
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-04-19
Release Date:
2022-08-03
Method Details:
Experimental Method:
Resolution:
2.90 Å
R-Value Free:
0.23
R-Value Work:
0.19
Space Group:
P 61 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:N-terminal endonuclease domain of La Crosse virus L-protein
Chain IDs:A (auth: AAA), B (auth: BBB), C (auth: DDD), D (auth: GGG)
Chain Length:184
Number of Molecules:4
Biological Source:Bunyavirus La Crosse
Primary Citation
Biophysical and structural study of La Crosse virus endonuclease inhibition for the development of new antiviral options.
Iucrj 11 374 383 (2024)
PMID: 38656310 DOI: 10.1107/S205225252400304X

Abstact

The large Bunyavirales order includes several families of viruses with a segmented ambisense (-) RNA genome and a cytoplasmic life cycle that starts by synthesizing viral mRNA. The initiation of transcription, which is common to all members, relies on an endonuclease activity that is responsible for cap-snatching. In La Crosse virus, an orthobunyavirus, it has previously been shown that the cap-snatching endonuclease resides in the N-terminal domain of the L protein. Orthobunyaviruses are transmitted by arthropods and cause diseases in cattle. However, California encephalitis virus, La Crosse virus and Jamestown Canyon virus are North American species that can cause encephalitis in humans. No vaccines or antiviral drugs are available. In this study, three known Influenza virus endonuclease inhibitors (DPBA, L-742,001 and baloxavir) were repurposed on the La Crosse virus endonuclease. Their inhibition was evaluated by fluorescence resonance energy transfer and their mode of binding was then assessed by differential scanning fluorimetry and microscale thermophoresis. Finally, two crystallographic structures were obtained in complex with L-742,001 and baloxavir, providing access to the structural determinants of inhibition and offering key information for the further development of Bunyavirales endonuclease inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures